Responses to Infant Immunisations
Conditions
Keywords
pertussis, maternal vaccination, maternal immunisation, immune response
Brief summary
Due to an unexpectedly high number of infant deaths from whooping cough in 2012, the Department of Health acted to protect newborns between birth and completion of primary immunisations, the period with greatest risk of disease. Vaccination of pregnant women with whooping cough vaccine in the third trimester of pregnancy was instigated nationally, so that antibodies produced by the Mum would cross the placenta to the unborn child, giving them passive protection at the most vulnerable time. This antibody transfer has been known for some time but has not been compared between the two whooping cough vaccines being used in pregnancy. Any effect the raised antibody might have on infant responses to the vaccines given in the first few months of life has also not been measured. This is particularly important as the infant immunisations include some of the same components as the whooping cough vaccines, which include diphtheria, tetanus and polio. Previous studies have shown that high levels of antibody prior to vaccination may affect subsequent antibody responses. It is therefore important to assess whether administration of the whooping cough vaccine in pregnancy adversely affects the protection afforded by the infant vaccines, particularly to those which are similar, namely tetanus and diphtheria as well as meningitis C and Hib vaccines which include diptheria and tetanus components in their structures. This study will assess immune responses of mothers and their babies (\ 200 pairs) to their vaccinations and will allow the comparison of two whooping cough vaccines being used in pregnancy. This will be done by taking small amounts of blood, which is the only way to measure antibody levels (the proxy of the immune response), before and after the vaccinations. A group of unvaccinated women and their babies (50 pairs) will also be recruited to allow comparison of their immune responses.
Interventions
DRUGRepevax
vaccine
DRUGBoostrix-IPV
vaccine
Sponsors
Institute of Child Health
St George's, University of London
Public Health England
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
16 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
Pregnant women who, at the time of enrolment • are aged 1645 years Infants of the women recruited will also be seen during the study. They will be given their immunisations according to the routine childhood immunisation schedule and will have blood samples collected as detailed in the clinical procedures section of this form. Their inclusion/ exclusion will be as per the Green Book recommendations by the UK Dept of Health.
Exclusion criteria
Participants may not be included in the study if any of the following apply: All women: * Bleeding disorder * Receipt of any pertussis containing vaccine in the previous 12 months Women to be vaccinated only (i.e. not the control group): * Received immunoglobulin or other blood product within the preceding 3 months * Fulfil any of the contraindications to vaccination specified in The Green Book on Immunisation (https://www.gov.uk/government/organisations/publichealthenglan d/series/immunisationagainstinfectiousdiseasethegreenbook), including: * A confirmed anaphylactic reaction to a previous dose of diphtheria, tetanus, pertussis or poliomyelitis containing vaccine * A confirmed anaphylactic reaction to any component of the vaccine * A confirmed anaphylactic reaction to a previous dose of diphtheria, tetanus, pertussis or poliomyelitis containing vaccine * Temporary
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PT immunogenicity (IgG GMC) | Birth, 2, 5 and 13 months of age | To compare antiPertussis Toxin (PT) IgG responses following primary immunisation with an acellular pertussiscontaining vaccine in infants born to mothers who received REPEVAX in pregnancy compared to infants whose mothers received BOOSTRIXIPV in pregnancy. |
| Immunogenicity of pertussis antigens (IgG GMC) | Birth, 2, 5 and 13 months of age | To compare antibody responses to pertussis antigens (concentration of IgG antibody to PT, pertactin (PRN), filamentous haemagglutinnin (FHA) and fimbrial antigens 2 and 3 (FIM 2 and 3\]), tetanus toxoid and diphtheria toxoid at birth amongst infants born to mothers who received REPEVAX in pregnancy compared to infants whose mothers received BOOSTRIXIPV in pregnancy |
| Immunogenicity of infant immunisations - pertussis antigens, meningococcal serogroup C, pnuemococcal vaccines at 2, 5 and 13 months of age, (all IgG GMC and SBA GMT for MenC) | Birth, 2, 5 and 13 months of age | To compare antibody responses to pertussis antigens \[IgG to PT, PRN, FHA and FIM 2 and 3\], Hib antigen \[PRP\], tetanus toxoid and diphtheria toxoid; meningococcal serogroup C serum bactericidal antibody titres and meningococcal serogroup Cspecific IgG concentrations; 13 serotypespecific pneumococcal IgG concentrations and functional pneumococcal antibody studies at 2, 5 and 13 months of age (just before and one month after primary immunization and one month after booster vaccines) in infants born to mothers who received REPEVAX in pregnancy compared to infants whose mothers received BOOSTRIXIPV in pregnancy and compared to infants whose mothers who did not receive pertussis vaccination in pregnancy |
Other
| Measure | Time frame | Description |
|---|---|---|
| immunogenicity of pnuemococcal conjugate vaccine | birth, 2, 5 13 months | immunogenicity of pnuemococcal conjugate vaccine |
| immunogenicity of pertussis vaccination | birth, 2, 5, 13 months | immunogenicity of pertussis vaccination |
| immunogenicity of meningococcal conjugate vaccine | birth, 2, 5, 13 months | immunogenicity of meningococcal conjugate vaccine |
| immunogenicity of diphtheria vaccine | borth 2, 5, 13 months | immunogenicity of diphtheria vaccine |
Countries
United Kingdom
Outcome results
None listed